Skip to main content

Science & Platform

Finding novel ways to selectively target and strike against cancer

Driven by advances in cancer biology, medicinal chemistry and data sciences over the last two decades, the field of cancer therapy has entered a new era of more targeted, genetic-based approaches.

Targeted therapies have been transformative for some patients to achieve long-term durable benefit. For most people with cancer, however, no highly effective precision therapies exist.

Scorpion Therapeutics harnesses the scientific breakthroughs of the past two decades in cancer biology, chemistry, and data sciences to extend the frontiers of oncology research and drug development and usher in the era of Precision Oncology 2.0.

Accelerating the era of Precision Oncology 2.0

Through our platform, we are developing a diversified and deep pipeline of optimized drug-discovery programs at unparalleled speed and scale compared to existing benchmarks.

Through our platform, we are developing a diversified and deep pipeline of optimized drug-discovery programs at unparalleled speed and scale compared to existing benchmarks.

Our drug hunting platform enables us to draw unique insights from proprietary biological and chemistry datasets to deliver precision therapeutic solutions to patients with cancer that currently do not benefit from precision oncology approaches.

Hover to Explore

Our Drug Hunting Platform

Science

Chemistry

Data

Our Process
Target-first Approach

We have advanced cutting-edge technologies to new levels of capability and integrated them with our own proprietary techniques and expertise to target cancer cell drivers with unparalleled precision.

In our mission to deliver a fast, precise, and lethal strike at a cancer’s unique drivers, we start with a clear target and product profile in mind:

  • Can selective target inhibition improve patients’ survival or quality of life beyond what’s possible with the current standard treatment?
  • Can the target be modulated to achieve therapeutic effects without causing significant toxicity?
  • Can inhibiting the target offer benefits as part of combination therapy?

We carefully select high-value targets that are present in specific patient populations and those underserved by current treatments. Then, our scientists get to work on how to achieve that profile.

We select targets where there is a clear opportunity for a precision medicine strategy to address the “therapeutic white spaces” of underserved populations. Because these targets are selected based on a mechanistic understanding of why specific patients are most likely to respond to our clinical candidates, we can generate proof-of-concept data in the earliest stages of the clinical development process.

Our product candidates aim to address three target categories in what we consider “therapeutic white spaces”:

  • Best-in-class molecules targeting validated oncogene targets
  • First-in-class molecules for previously undruggable targets
  • First-in-class molecules for novel cancer targets

See our pipeline

Learn More